Short-chain lipopolysaccharide mutants of serogroup B Neisseria meningitidis of potential value for production of outer membrane vesicle vaccines
- PMID: 8559044
- DOI: 10.1006/mpat.1995.0054
Short-chain lipopolysaccharide mutants of serogroup B Neisseria meningitidis of potential value for production of outer membrane vesicle vaccines
Abstract
Four lipopolysaccharide (LPS) mutants (Mu-1 to Mu-4) were isolated after exposing Neisseria meningitidis strain 44/76 to pyocins from Pseudomonas aeruginosa. Parent strain LPS contained one major SDS-PAGE band expressing the immunotype determinants of L3, L3,7 and L3,7,9 and a minor band of higher mobility expressing the immunotype determinants of L8, L8a, L1,8,10 and L11. Each mutant LPS appeared as one SDS-PAGE band of higher mobility than the bands of the parent strain. None of these LPSs expressed the immunotype determinants of the parent strain, except Mu-4 LPS which reacted with the L11-specific MAb 4C4. Strain 44/76 LPS was found to contain galactose (Gal), glucose (Glc), heptose (Hep), glucosamine (GlcN), and 2-keto-3-deoxy-octulosonic acid (Kdo) in the molar ratios of 1.9:1.3:1.7:3.5:2.1. The corresponding ratios of the mutants were: Mu-4, 0:1.7:1.7:2.8:2.0; Mu-3, 0:0:1.7:2.4:1.6; Mu-2, 0:0:2.1:1.8:2.0, Mu-1, 0:0:1.8:1.9. Thus, all mutant LPSs lacked Gal and possessed less GlcN as compared to strain 44/76 LPS. Consequently, these mutants do not express the lacto-N-neo-tetraose (Gal1-4GlcN1-3Gal1-4Glc) commonly found as a part of meningococcal LPS and also on structures of human erythrocytes. These LPS mutants will be considered for use in production of OMV vaccines without host-like antigens, which might favour induction of antibodies to more conserved epitopes of meningococcal LPS.
Similar articles
-
Outer membrane vesicle vaccines made from short-chain lipopolysaccharide mutants of serogroup B Neisseria meningitidis: effect of the carbohydrate chain length on the immune response.Vaccine. 1997 Aug;15(11):1225-34. doi: 10.1016/s0264-410x(97)00030-3. Vaccine. 1997. PMID: 9286048
-
Lipopolysaccharide heterogeneity and escape mechanisms of Neisseria meningitidis: possible consequences for vaccine development.Microb Pathog. 1997 Sep;23(3):139-55. doi: 10.1006/mpat.1997.0143. Microb Pathog. 1997. PMID: 9281472
-
Candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: developmental chemistry and investigation of immunological responses following immunization of mice and rabbits.Vaccine. 2005 Oct 17;23(43):5045-54. doi: 10.1016/j.vaccine.2005.06.011. Vaccine. 2005. PMID: 16046037
-
Molecular mimicry of host structures by lipooligosaccharides of Neisseria meningitidis: characterization of sialylated and nonsialylated lacto-N-neotetraose (Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc) structures in lipooligosaccharides using monoclonal antibodies and specific lectins.Adv Exp Med Biol. 2001;491:525-42. doi: 10.1007/978-1-4615-1267-7_35. Adv Exp Med Biol. 2001. PMID: 14533820 Review.
-
Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.Vaccine. 2009 Jun 24;27 Suppl 2:B3-12. doi: 10.1016/j.vaccine.2009.04.071. Epub 2009 May 28. Vaccine. 2009. PMID: 19481313 Review.
Cited by
-
Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial.Infect Immun. 1998 Jul;66(7):3223-31. doi: 10.1128/IAI.66.7.3223-3231.1998. Infect Immun. 1998. PMID: 9632589 Free PMC article.
-
Neisseria gonorrhoeae lipooligosaccharide glycan epitopes recognized by bactericidal IgG antibodies elicited by the meningococcal group B-directed vaccine, MenB-4C.Front Immunol. 2024 Feb 19;15:1350344. doi: 10.3389/fimmu.2024.1350344. eCollection 2024. Front Immunol. 2024. PMID: 38440731 Free PMC article.
-
Antimicrobial Weapons of Pseudomonas aeruginosa.Adv Exp Med Biol. 2022;1386:223-256. doi: 10.1007/978-3-031-08491-1_8. Adv Exp Med Biol. 2022. PMID: 36258074
-
Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.Clin Vaccine Immunol. 2007 Jul;14(7):830-8. doi: 10.1128/CVI.00039-07. Epub 2007 May 9. Clin Vaccine Immunol. 2007. PMID: 17494638 Free PMC article. Clinical Trial.
-
A critical role for ATF2 transcription factor in the regulation of E-selectin expression in response to non-endotoxin components of Neisseria meningitidis.Cell Microbiol. 2016 Jan;18(1):66-79. doi: 10.1111/cmi.12483. Epub 2015 Jul 31. Cell Microbiol. 2016. PMID: 26153406 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials